TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
Provided By PR Newswire
Last update: May 2, 2025
Split designed to achieve compliance with Nasdaq minimum bid price requirements
BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-28 reverse stock split. The reverse stock split was approved by TransCode's stockholders on May 2, 2025, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
Read more at prnewswire.comNASDAQ:RNAZ (6/5/2025, 3:04:53 PM)
7.245
-0.14 (-1.96%)
Find more stocks in the Stock Screener
RNAZ Latest News and Analysis
17 days ago - ChartmillWhich stocks are experiencing notable movement on Monday?Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
17 days ago - ChartmillTop stock movements in today's session.Here are the top movers in Monday's session, showcasing the stocks with significant price changes.
